Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions

Authors:

Abstract
Physiologically based pharmacokinetic (PBPK) modeling for itraconazole using a ′bottom-up′ approach is challenging. Not only due to complex saturable pharmacokinetics (PK) and presence of three metabolites exhibiting CYP3A4 inhibition, but also because discrepancies in reported in vitro data. The overall objective of this study is to provide a comprehensive mechanistic PBPK model for itraconazole to increase the confidence in its drug-drug interaction (DDI) predictions. To achieve this, key in vitro and in vivo data for itraconazole and its major metabolites were generated. This data was crucial to develop a novel ′bottom-up′ PBPK model in Simcyp® for itraconazole and two of its major metabolites: hydroxy- itraconazole (OH-ITZ) and keto-itraconazole (keto-ITZ). Performance of the model was validated using pre-specified acceptance criteria against different dosing regimens, formulations for 29 PK and DDI studies with midazolam and other CYP3A4 substrates. The main outcome is an accurate PBPK model that simultaneously predicts the PK profiles of itraconazole, OH-ITZ and keto-ITZ. In addition, DDI between midazolam and itraconazole were successfully predicted within a 2-fold error for all the studies. Prediction precision and bias of DDI expressed as geometric mean fold error were for the area under the concentration- time curve and peak concentration, 1.06 and 0.96, respectively. To conclude, in this paper a comprehensive dataset for itraconazole and its metabolites is provided that enables bottom-up mechanism based PBPK modeling. The presented model is applicable for studying the contribution from the metabolites and allows improved assessments of itraconazole DDI.

This publication has 59 references indexed in Scilit: